Company Overview and News
Shares of GoPro Inc. GPRO, +3.92% shot up 5% in premarket trade Wednesday, after Oppenheimer analyst Andrew Uerkwitz turned bullish on the action camera maker, citing optimism surrounding new product launches and a new focused strategy. Uerkwitz raised his rating to outperform from perform, and issued a stock price target of $9, which is 36% above Tuesday's closing price of $6.62, and would be the highest price seen since November 2017.
GoPro (GPRO) released the Hero 7 cameras on September 20. Yes, cameras plural. I have written quite a bit about GoPro product development issues. GoPro has been releasing products that were not ready, not tested and badly thought out. A note written on a black board in a development lab I worked said, “Stick to your knitting!!!” After three years of product releases bringing GoPro close to disaster they read the message.
Action camera company GoPro (NASDAQ:GPRO) unveiled its lineup of new products on Thursday, launching just ahead of this year’s all-important holiday shopping season. GoPro stock rallied a bit because, well, at least a small faction of investors rev up their bullishness whenever the company makes any sort of move.
GPRO FB FIT SNAP
2018-09-25 investorplace - 1
Roku (NASDAQ:ROKU) has been on a winning streak this summer. In just a few months, ROKU stock is up more than 50%. Previously, Roku had seen more sideways trading as investors and analysts considered various pros and cons affecting the company.
SONO GPRO FIT AMZN ROKU NFLX DIS
2018-09-23 investorplace - 1
The story sounded like a good one at the time. Snap (NYSE:SNAP), the parent company of messaging platform Snapchat, was following in the footsteps of highly successful social networking companies like Facebook (NASDAQ:FB) and Twitter (NYSE:TWTR). Surely SNAP stock would be a winner, too.
GPRO GRPN FB GOOGL TWTR GOOG SNAP
Shares of GoPro Inc. GPRO, +1.58% are up 2% in Thursday morning trading after the company announced its new Hero7 family of cameras. The Hero7 Black camera, which goes for $399, has what the company calls "the best in-camera video stabilization ever featured in a camera" as well as live-streaming abilities. The company also announced its new $299 Hero7 Silver and $199 Hero7 White cameras, which are waterproof to 33 feet and support voice commands.
These were once a group of the market’s highest flyers, as a mass exodus of advertising dollars from traditional channels to digital channels caused digital advertiser’s revenues, profits and stock prices to shoot higher.
FB FIT PYPL NFLX GOOG GPRO MTCH BABA AMZN SPOT GOOGL TWTR ROKU VZ MSFT BIDU TTD SNAP
2018-09-12 investorplace - 1
Some companies don’t get it right the first time. Wireless and home speaker manufacturer Sonos (NASDAQ:SONO) just reported its first quarterly numbers as a public company. They didn’t live up to expectations. Sonos stock dropped.
SONO GPRO FB FIT AMZN GOOGL ROKU AAPL GOOG
The rise and fall of Fitbit (NYSE:FIT) and GoPro (NASDAQ:GPRO) has made many investors wary of wearables stocks. Indeed, when one takes more of a macro perspective, some of these names can look like no-moat companies who take a sensor and linking it to an app.
HMI GPRO FIT NKE GOOGL GRMN AAPL GOOG FOSL
Many investors, unless they’re venture capitalists, tend to think of startups as something that exist in a different land. While it’s fun to hear about innovation and possibilities, the average investor isn’t afforded many opportunities to put their money into a startup. The main options are crowdfunding platforms or a handful of ETFs that target new kids on the block. So it’s hard to know which startups to watch.
GPRO MSFT CRM
Good morning. My name is Josh Kehoe. On behalf of Jim Suva, Citi's IT Hardware, Electronic Manufacturing Services and Telecom Equipment and Networking Analyst. I would like to welcome you all to Citi's 2018 Global Tech Conference Day 2.
After Ambarella (NASDAQ:AMBA) posted quarterly results, the stock tanked by around $5 at the open. The weak near-term outlook and the quarterly loss of $0.21 a share should concern investors. Despite the promise of CV, or computer vision, Ambarella is still a “show me” company.
GPRO AMBA NVDA INTC
A forecast-induced near-wipeout in Ambarella (NASDAQ:AMBA) following earnings may be setting up a sunnier long-term outlook. But if you’re looking for a more stable ride in AMBA stock, a bullish combined spread position with limited and reduced risk is one to consider. Let me explain.
2018-08-23 - Asif
Overview GoPro is enabling the way people capture and share their lives from a perspective only achieved with a GoPro. What began as an idea to help athletes document themselves engaged in sport, GoPro has become a mobile storytelling solution that helps the world share itself through immersive content. Helping people capture, share experiences and manage content is at the core of its business. GoPro is committed to developing solutions that create an easy, seamless experience for consumers to capture, create, enjoy and store engaging personal content. When consumers use its products and services, those products and services enable compelling, authentic content that organically increases awareness for GoPro, driving a virtuous cycle and a self-reinforcing demand for its products. The company believe revenue growth may be driven by the introduction of new cameras, offerings, accessories and software applications. The company believe new camera features and related services dr...
18h - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
Silicon Investor Message Boards
This table lists all message boards related to GPRO / GoPro, Inc. on message board site Silicon Investor.
|GoPro - Be A Hero||GoPro - Be A Hero||GoPro - Be A Hero|
as of ET